iTeos to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 12, 2021
iTeos Therapeutics, Inc. (Nasdaq: ITOS) will host a conference call on August 12, 2021, at 8:00 a.m. ET to report its second quarter 2021 financial results and offer a corporate update. The event will be accessible via a pre-registration link and a live audio webcast available on the company's investor relations website. iTeos is focused on immuno-oncology therapeutics with ongoing trials for EOS-448, an anti-TIGIT antibody, and inupadenant, an adenosine A2A receptor antagonist. Preliminary data indicates potential clinical activity and favorable tolerability for both candidates.
- Ongoing Phase 1 clinical trial of EOS-448 showing preliminary clinical activity and favorable tolerability.
- Advancing inupadenant in clinical development; preliminary results suggest encouraging single-agent activity.
- None.
CAMBRIDGE, Mass. and GOSSELIES, Belgium, Aug. 05, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that it will host a conference call and live webcast at 8:00 a.m. ET on Thursday, August 12, 2021 to report its second quarter 2021 financial results and provide a corporate update.
To pre-register for the call, please use the following link, and you will receive access details via email.
Webcast
This registration link, along with a live audio webcast, will be accessible from the Events page of the Company’s IR website at https://investors.iteostherapeutics.com/news-and-events/events. A replay will be available on the Company’s website approximately two hours after completion of the event and for 30 days following the call
About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. The Company’s innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology. The initial antibody product candidate, EOS-448, is a high affinity, potent, anti-TIGIT antibody with a functional Fc domain, designed to enhance the anti-tumor response through a multifaceted immune modulatory mechanism. An open-label Phase 1 clinical trial of EOS-448 is ongoing in adult cancer patients with advanced solid tumors with preliminary data indicating preliminary clinical activity as a monotherapy and a favorable tolerability profile. The Company is also advancing inupadenant, a first insurmountable adenosine A2A receptor antagonist in clinical development tailored to overcome cancer immunosuppression. iTeos is conducting an open-label multi-arm Phase 1/2a clinical trial of inupadenant in adult cancer patients with advanced solid tumors. Preliminary results indicate encouraging single-agent activity as well as the identification of a potential predictive biomarker. iTeos Therapeutics is headquartered in Cambridge, MA with a research center in Gosselies, Belgium.
For further information, please contact:
Investor Contact:
Ryan Baker
iTeos Therapeutics, Inc.
Ryan.Baker@iteostherapeutics.com
Media Contacts:
media@iteostherapeutics.com
FAQ
When will iTeos Therapeutics report its Q2 2021 financial results?
What is the stock symbol for iTeos Therapeutics?
What are the clinical programs currently in development at iTeos?
How can I access the conference call and webcast for iTeos Therapeutics?
